Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Long-Term Deferred Tax (2018)

CytomX Therapeutics (CTMX) has disclosed Long-Term Deferred Tax for 1 consecutive years, with $1.1 million as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Long-Term Deferred Tax changed N/A year-over-year to $1.1 million, compared with a TTM value of $1.1 million through Dec 2018, changed N/A, and an annual FY2018 reading of $1.1 million, changed N/A over the prior year.
  • Long-Term Deferred Tax was $1.1 million for Q4 2018 at CytomX Therapeutics.
  • Across five years, Long-Term Deferred Tax topped out at $1.1 million in Q4 2018 and bottomed at $1.1 million in Q4 2018.